Bullish Lilly Adds New Alzheimer's Candidate To Clinical Portfolio

Undaunted by its recent disappointment with solanezumab, Eli Lilly is adding another clinical-stage Alzheimer's disease candidate to its portfolio through an agreement with AstraZeneca.